p38-MAPK

p38α inhibitor 5 is a PROTAC-type ligand that specifically targets p38α MAP kinase. This compound is designed to facilitate the degradation of p38α, providing a valuable tool for studying the enzyme's role in cellular signaling and inflammation. It is suitable for applications in drug discovery and therapeutic research, particularly in the context of conditions associated with p38α dysregulation.

Org 48762-0 is a selective p38 inhibitor, exhibiting a potent EC50 of 0.1 μM for p38α kinase. This compound demonstrates a high degree of specificity for both p38α and p38β over other kinases, allowing for targeted therapeutic interventions. Org 48762-0 effectively reduces lipopolysaccharide-induced TNFα release, making it a valuable tool in the study of inflammatory diseases. Its applications extend to researching conditions such as rheumatoid arthritis and Werner syndrome.

Cyclocurcumin is a potent inhibitor of p38α, a key signaling molecule involved in inflammatory responses. It demonstrates significant antirheumatic, antivasoconstrictive, and antioxidant activities. This compound is valuable for research applications focused on inflammation, cardiovascular diseases, and oxidative stress.

PF-05381941 is a potent dual inhibitor of TAK1 and p38α, exhibiting IC50 values of 156 nM and 186 nM, respectively. This compound effectively modulates the MAPK signaling pathway, making it a valuable tool for investigating cellular responses to stress and inflammation. PF-05381941 is commonly utilized in research focused on cancer, autoimmune diseases, and other pathological conditions linked to dysregulated kinase activity.

RO3201195 is a selective inhibitor of p38 MAPK, a key signaling molecule involved in inflammatory responses and cellular stress. This compound demonstrates potent inhibition of WS cell proliferation, with an IC50 value of 190 nM. RO3201195 is suitable for research applications aimed at understanding the role of p38 MAPK in various biological processes, including inflammation and cancer.